Company News
Climb Bio CLYM116 Data Sparks 2.7% Drop
Climb Bio Inc presented initial Phase 1 safety data for its anti‑APRIL antibody CLYM116 at the European Renal Association Congress in Glasgow.
The data, from 49 healthy volunteers, showed no serious a
